MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]
Many of our current shareholders have many questions as to what AngioSoma, Inc. is doing, so we are making a shareholder presentation available (the PDF version available here) to all of our shareholders. We intend to update this as we progress in our business plan. © 2016 by AngioSoma, Inc., all rights reserved.
Montgomery, Texas (September 21, 2016) – AngioSoma, Inc. (the ‘Company‘, ‘we‘, and ‘our‘), announces the formation of the Soma Nutraceuticals, Inc. subsidiary for the acquisition and marketing of proven nutraceutical products, as well as acquisition discussions with multiple proven nutraceutical intellectual properties. Our Chairman Emeritus “Doc” Summers owns some of the proven nutraceutical products we Read more about AngioSoma, Inc. enters discussions with Nutraceutical Intellectual Property Owners[…]
July 28, 2016 MONTGOMERY, Texas–(BUSINESS WIRE)– AngioSoma, Inc. (SOAN) (the ‘Company,’ ‘we,’ and ‘our‘), announces the formation of its scientific advisory board with the addition of A. Tomas Garcia III, MD, a practicing physician in the field of cardiology for the past 35 years and the immediate past president of the Texas Medical Association. Dr. Read more about AngioSoma, Inc. Welcomes Dr. Tom Garcia to Scientific Advisory Board[…]
July 14, 2016 09:00 AM Eastern Daylight Time MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN), previously known as First Titan Corp. (the ‘Company‘, ‘we‘, and ‘our‘), changed our corporate name and focus to that of a clinical stage biopharmaceutical company introducing an exciting new treatment for one of the world’s most insidious and pervasive diseases, peripheral artery Read more about AngioSoma’s Corporate Focus[…]
HOUSTON, TX / ACCESSWIRE / June 22, 2016 / First Titan Corp. (OTCQB: FTTN) (the “First Titan”) is proud to announce the acquisition of AngioSoma, Inc., (OTCQB: SOAN) (the “Company”). The acquisition of AngioSoma, Inc. provides diversification for First Titan outside of the depressed oil & gas industry under the new name AngioSoma, Inc. and Read more about First Titan Corp. Acquired AngioSoma, Inc.[…]
Feb 25, 2016 OTC Disclosure & News Service Despite falling crude prices, American investors have not lost hope in energy, a sentiment companies across the sector, including First Titan Corp. (OTCQB: FTTN), plan to tap into as they collectively seek to raise a combined $4.6 billion in equity this quarter. That impressive total represents nearly Read more about FTTN: Investors Ignore Oil Slump, Keep Pouring Big Money into Energy Industry[…]